Literature DB >> 33835097

Reply to the Letter to the Editor: Short-term Revision Risk of Patellofemoral Arthroplasty is High: An Analysis From Eight Large Arthroplasty Registries.

Peter L Lewis1.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 33835097      PMCID: PMC8133230          DOI: 10.1097/CORR.0000000000001718

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.755


× No keyword cloud information.
  4 in total

1.  Similar postoperative patient-reported outcome in both second generation patellofemoral arthroplasty and total knee arthroplasty for treatment of isolated patellofemoral osteoarthritis: a systematic review.

Authors:  Kristine Ifigenia Bunyoz; Sébastien Lustig; Anders Troelsen
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2018-09-28       Impact factor: 4.342

2.  Patellofemoral arthroplasty versus total knee arthroplasty for patients with patellofemoral osteoarthritis: equal function and satisfaction but higher revision rate for partial arthroplasty at a minimum eight years’ follow-up.

Authors:  N D Clement; T A Howard; R J Immelman; D MacDonald; J T Patton; G M Lawson; R Burnett
Journal:  Bone Joint J       Date:  2019-01       Impact factor: 5.082

3.  Patellofemoral arthroplasty is cheaper and more effective in the short term than total knee arthroplasty for isolated patellofemoral osteoarthritis: cost-effectiveness analysis based on a randomized trial.

Authors:  Charlotte Fredborg; Anders Odgaard; Jan Sørensen
Journal:  Bone Joint J       Date:  2020-04       Impact factor: 5.082

4.  Short-term Revision Risk of Patellofemoral Arthroplasty Is High: An Analysis from Eight Large Arthroplasty Registries.

Authors:  Peter L Lewis; Francois Tudor; Michelle Lorimer; John McKie; Eric Bohm; Otto Robertsson; Keijo T Makela; Jaason Haapakoski; Ove Furnes; Christoffer Bartz-Johannessen; Rob G H H Nelissen; Liza N Van Steenbergen; Donald C Fithian; Heather A Prentice
Journal:  Clin Orthop Relat Res       Date:  2020-06       Impact factor: 4.755

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.